A drop of blood could spot a deadly liver disease in newborns

NCT ID NCT03898765

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This trial is testing whether a dry blood spot test—using a tiny sample from a newborn's heel—can screen for biliary atresia, a serious liver condition that blocks bile flow. The test measures certain biomarkers (direct bilirubin, γ-GT, and MMP-7) that may be elevated in affected babies. The goal is to enable earlier diagnosis and treatment, which could improve survival. The study will include newborns born in Shanghai.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Dry blood spot screening measuring biomarkers (direct bilirubin, γ-GT, MMP-7)
What this could lead to
If successful, this could lead to a routine newborn screening test that catches biliary atresia early, potentially saving lives through timely surgery.
What could go wrong
This is an early-stage diagnostic study, and the test may not be accurate enough for widespread use. False positives or negatives could occur, and more research is needed before it becomes standard.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY ATRESIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Shanghai Xinhua Hospital, affiliated to Shanghai Jiao Tong University, School of Medicine

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.